lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma

Table 1

Clinical features of 57 LAD patients and the relative expression levels of RP11-838N2.3.

Term	Case ()	Relative expression level	Kruskal-Wallis test or Mann-Whitney test
Sex			234.00	0.453
Male	28	40.21 (30.13-51.32)
Female	29	41.42 (29.12-52.35)
TMN stage			10.124	0.414
Ia	12	38.67 (29.54-51.56)
Ib	28	38.92 (30.41-52.34)
IIa	7	40.85 (30.83-51.83)
IIb	2	41.23 (31.92-51.72)
IIIa	8	41.10 (32.34-52.12)
Histological degree			11.456	0.321
Poor	11	38.13 (29.12-49.23)
Poor-moderate	7	37.43 (30.87-50.54)
Moderate	17	40.82 (31.54-51.82)
Moderate-high	9	41.34 (30.12-50.01)
High	13	41.39 (31.56-51.34)
Lymph node metastasis			3.213	0.009
Yes	14	60.37 (42.94-72.34)
No	43	31.40 (21.84-42.84)
Smoking			267.00	0.672
Yes	20	40.23 (30.34-51.56)
No	37	41.56 (31.41-52.19)